Lexaria Bioscience (LEXX) received lead clinical site human research ethics committee approval that was required before dosing can begin in the 5th study arm of the Company’s Phase 1b, 12-week chronic study GLP-1-H24-4, in Australia. This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of the Study. The Company is pleased to have received all of the necessary lead clinical site approvals so quickly. Additional HREC approval is still pending for the other clinical sites, which is expected soon. The Study is progressing with both patient recruitment and dosing. The milestone of First Patient First Dose occurred in December 2024 as planned.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication
- Lexaria to investigate commercial opportunities for DehydraTECH-Liraglutide
- Lexaria Secures Two New Patents for Epilepsy Treatment with DehydraTECH
- Lexaria Bioscience granted two new DehydraTECH patents
- Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1